← Back to Search

Neuromodulation Device

Neuromodulation Techniques for Spinal Cord Injury

Phase 2
Recruiting
Led By Ashraf Gorgey, PhD PT
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants will be between 18-70 years old, male, with traumatic motor complete SCI and level of injury of T10 and above, as determined by EMG testing and International Standards for Neurological Classification of SCI (ISNCSCI) exam
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights

Study Summary

This trial is testing if a robotic suit can help people with spinal cord injuries walk, which could help with other health problems associated with the injury.

Who is the study for?
This trial is for males aged 18-70 with traumatic motor complete spinal cord injury (SCI) at T10 level or above. They must have specific motor deficits, functional limb range of motion, and pass safety assessments like the Modified Ashworth Scale. Excluded are those with other neurological injuries, unhealed fractures, severe scoliosis or contractures that prevent exoskeleton use, certain implanted devices, low bone density scores, untreated severe conditions such as hypertension or diabetes.Check my eligibility
What is being tested?
The study tests two rehabilitation techniques for SCI: one combines an exoskeleton suit with spinal cord epidural stimulation (EAW+SCES), and the other pairs the suit with transspinal stimulation (EAW+TS). The goal is to improve standing and walking abilities while reducing health issues related to SCI.See study design
What are the potential side effects?
Potential side effects may include discomfort from wearing the exoskeleton or during stimulation procedures. There might also be risks of skin irritation where electrodes are placed for stimulation and muscle fatigue due to physical therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man aged 18-70 with a severe spinal cord injury above T10.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
10-meter walking speed (m/sec)
Muscles electromyography (EMG) activity (micro-volts)
Secondary outcome measures
Fasting lipid profile (mg/dl)
Fat mass and fat-free mass (kg)
Oxygen Uptake (ml/min)
Other outcome measures
Urinary Bladder

Trial Design

2Treatment groups
Experimental Treatment
Group I: EAW+TSExperimental Treatment1 Intervention
Three months of exoskeleton training followed by 6 months of transspinal stimulation.
Group II: EAW+SCESExperimental Treatment1 Intervention
Three months of exoskeleton training followed by 6 months of epidural stimulation.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,621 Previous Clinical Trials
3,323,491 Total Patients Enrolled
Virginia Commonwealth UniversityOTHER
700 Previous Clinical Trials
22,886,810 Total Patients Enrolled
Ashraf Gorgey, PhD PTPrincipal InvestigatorHunter Holmes McGuire VA Medical Center, Richmond, VA
2 Previous Clinical Trials
38 Total Patients Enrolled

Media Library

EAW+SCES (Neuromodulation Device) Clinical Trial Eligibility Overview. Trial Name: NCT04241250 — Phase 2
Spinal Cord Injury Research Study Groups: EAW+TS, EAW+SCES
Spinal Cord Injury Clinical Trial 2023: EAW+SCES Highlights & Side Effects. Trial Name: NCT04241250 — Phase 2
EAW+SCES (Neuromodulation Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04241250 — Phase 2
~0 spots leftby Jul 2024